1.0君实生物/en/js3333线路检测中心(中国)有限公司-Baidu百科rich600338Junshi Biosciences Announces Acceptance of the New Drug Application for JS002 (anti-PCSK9 mAb)
/wp-content/uploads/2023/04/JS002-副本.png1024683SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the new drug application for the company’s recombinant humanized anti-PCSK9 monoclonal antibody (product code: JS002) by the National Medical Products Administration (“NMPA”).